サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：多発性骨髄腫（MM）の世界市場2023-2030
市場調査レポート
商品コード
1292935

多発性骨髄腫（MM）の世界市場2023-2030

Global Multiple Myeloma Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 170 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
多発性骨髄腫（MM）の世界市場2023-2030
出版日: 2023年05月23日
発行: Orion Market Research
ページ情報: 英文 170 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多発性骨髄腫（MM）市場は、予測期間中に4.8%というかなりのCAGRで成長すると予測されています。市場の成長は、多発性骨髄腫（MM）の有病率の増加や診断・治療技術の進歩などの要因に起因しています。例えば、カリフォルニア大学によると、2020年には世界全体で176,404例、95％近くの多発性骨髄腫（MM）の新規症例が報告されました。また、カナダがん協会によると、2022年に新たに診断された骨髄腫患者数は4,000人で、そのうち男性が2,400人、女性が1,550人で、毎日11人近くが骨髄腫と診断されています。しかし、新たに開発された標的治療や移植技術の導入により、多発性骨髄腫（MM）の発症率は低下しています。例えば、2023年2月、Memorial Sloan Kettering Cancer Center（MSK）の研究者らは、再発性多発性骨髄腫（MM）の患者が、疾患の経過の早い段階でキメラ抗原受容体（CAR）T療法を受けることで恩恵を受けるという臨床試験の結果を発表しました。この治療では、完全寛解率が7倍近く増加し、治療後に体内でがんは検出されませんでした。

セグメント別の展望

多発性骨髄腫（MM）の世界市場では、Hyperdiploid（HMM）サブセグメントが大きな市場シェアを占めると予想される

タイプ別セグメントのうち、Hyperdiploid（HMM）サブセグメントは予測期間中に大きな成長を記録すると予測されています。HMMサブセグメントの成長は、研究開発活動の増加や個別化医療に対する需要の高まりなどの要因によるものです。例えば、2021年にJanssen Biotech, Inc.は、新規診断または再発/難治性多発性骨髄腫（MM）患者の治療薬としてDARZALEX FASPRO（daratumumab・hyaluronidase-fihj）の米国FDA承認を発表しました。

地域別展望

北米地域が多発性骨髄腫（MM）市場を独占すると予測

同地域の市場成長を牽引しているのは、Novartis AG、Bristol Myers Squibb、Amgen Inc.、 AbbVieなどの主要プレイヤーの存在と、多発性骨髄腫（MM）治療薬の上市数、新製品承認数の増加です。例えば、2022年1月、Bristol-Myers Squibbは、B細胞成熟抗原（BCMA）指向性キメラ抗原受容体（CAR）T細胞免疫療法であるAbecma（idecabtagene vicleucel）を、再発または難治性（R/R）の多発性骨髄腫（MM）の成人患者の治療薬として厚生労働省が承認したと発表しました。さらに、2021年12月、Amgenは、米国食品医薬品局（FDA）が、1～3ライン治療を受けた再発または難治性の多発性骨髄腫（MM）の成人患者に対する治療として、KYPROLIS（carfilzomib）の米国処方情報に、DARZALEX FASPRO（R）（daratumumab・hyaluronidase-fihj）およびdexamethasoneとの併用療法を追加することを承認したと発表しました。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Abbott Laboratories
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Amgen Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • GlaxoSmithKline plc
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Merck & Co., Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Novartis AG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 多発性骨髄腫（MM）の世界市場：薬剤クラス別
    • 免疫調節薬
    • プロテアソーム阻害剤
    • Anit-CD38モノクローナル抗体
    • アルキル化剤
    • その他
  • 多発性骨髄腫（MM）の世界市場：タイプ別
    • Hyperdiploid（HMM）
    • 非Hyperdiploid、またはHypodiploid
  • 多発性骨髄腫（MM）の世界市場：流通チャネル別
    • 病院薬局
    • 小売薬局・ドラッグストア
    • オンライン薬局

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Aurobindo Pharma
  • Aurobindo Pharma Ltd.
  • Bristol-Myers Squibb Co.
  • Cipla Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Genentech, Inc.
  • Hikma Pharmaceuticals PLC
  • Karyopharm Therapeutics Inc.
  • Oncopeptides AB
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceuticals U.S.A., Inc.
  • Teva Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 2. GLOBAL IMMUNOMODULATORS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PROTEASOME INHIBITOR FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ANTI-CD38 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL ALKYLATING AGENTS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL OTHER DRUGS FOR FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 8. GLOBAL HYPERDIPLOID (HMM) MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL NON-HYPERDIPLOID OR HYPODIPLOID MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 11. GLOBAL MULTIPLE MYELOMA IN HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL MULTIPLE MYELOMA IN RETAIL PHARMACIES & DRUG STORES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL MULTIPLE MYELOMA IN ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 19. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 21. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY DRUG CLASS, 2022 VS 2030 (%)
  • 2. GLOBAL IMMUNOMODULATORS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL PROTEASOME INHIBITORS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ANTI-CD38 MONOCLONAL ANTIBODY FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL ALKYLATING AGENTS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL OTHER DRUGS FOR MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 8. GLOBAL HYPERDIPLOID (HMM) MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL NON-HYPERDIPLOID OR HYPODIPLOID MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 11. GLOBAL MULTIPLE MYELOMA IN HOSPITAL PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL MULTIPLE MYELOMA IN RETAIL PHARMACIES & DRUG STORES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL MULTIPLE MYELOMA IN ONLINE PHARMACIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL MULTIPLE MYELOMA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD MULTIPLE MYELOMA MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027318

Global Multiple Myeloma Market Size, Share & Trends Analysis Report by Drug Class (Immunomodulators, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibody, Alkylating Agents, and Others), by Type (Hyperdiploid, and Non-Hyperdiploid or Hypodiploid), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies) Forecast Period (2023-2030)

The global multiple myeloma market is anticipated to grow at a considerable CAGR of 4.8% during the forecast period. The growth of the market is attributed to factors such as the increasing prevalence of multiple myeloma and advancements in diagnostic and treatment technologies. For instance, according to the University of California, in 2020, nearly 176,404 or 95% new cases of multiple myeloma were reported globally. Moreover, according to the Canadian Cancer Society, the number of new myeloma cases diagnosed in 2022 was 4,000, among them 2,400 males and 1,550 females, and nearly 11 people are diagnosed with myeloma each day. However, due to the introduction of newly developed targeted therapies and transplantation techniques, the rate of multiple myeloma get reduced. For instance, in February 2023, investigators at Memorial Sloan Kettering Cancer Center (MSK) published results from a clinical trial that found people with recurrent multiple myeloma get benefited from receiving chimeric antigen receptor (CAR) T therapy earlier in the course of their disease. With this therapy there was a nearly sevenfold increase in complete remission rates, and no cancer was detected in the body after the treatment.

Segmental Outlook

The global multiple myeloma market is segmented based on its drug class, type, and distribution channel. Based on the drug class, the market is sub-segmented into immunomodulators, proteasome inhibitor, anti-CD38 monoclonal antibody, alkylating agents, and others. Based on its type, the market is bifurcated into hyperdiploid (HMM) and non-hyperdiploid or hypodiploid. Further, based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies. Among the distribution channel, the hospital sub-segment is projected to exhibit the highest growth, owing to the availability of trained medical staff in hospitals that provide better services to patients along with an increase in patient admission in hospitals.

Hyperdiploid (HMM) Sub-Segment Expected to Hold a Major Market Share in the Global Multiple Myeloma Market

Among the type segment, the hyperdiploid (HMM) sub-segment is anticipated to register significant growth for the forecast period. The growth of the HMM sub-segment is attributed to factors such as increasing R&D activities and rising demand for personalized medicine. For instance, in 2021, Janssen Biotech, Inc. announced the US FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed or relapsed/refractory multiple myeloma.

Regional Outlooks

The global multiple myeloma market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, North America is anticipated to grow at a significant CAGR over the forecast period. The growth is attributed to a rise in number of government funding organizations for R&D of cancer and increase in prevalence of multiple myeloma.

Global Multiple Myeloma Market Growth, by Region 2023-2030

Source: OMR Analysis

The North America Region Anticipated to Dominate the Multiple Myeloma Market

The growth of the market in the region is driven by the presence of key players such as Novartis AG, Bristol Myers Squibb, Amgen Inc., AbbVie, and others, coupled with an increase in the number of product launches, and new product approvals for multiple myeloma drugs. For instance, in January 2022, Bristol-Myers Squibb announced that Japan's Ministry of Health, Labor and Welfare approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma. Moreover, in December 2021, Amgen announced that the US Food and Drug Administration (FDA) approved the expansion of the KYPROLIS (carfilzomib) US prescribing information to include its use in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Market Players Outlook

The major companies serving the global multiple myeloma market include: Abbott Laboratories, Amgen Inc., GlaxoSmithKline plc, Merck & Co., Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating multiple myeloma named TNB-383B. TNB-383B is a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. Through this partnership, both companies aim to develop and commercialize TNB-383B, a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's immune system to target and kill BCMA-expressing tumor cells.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global multiple myeloma market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbott Laboratories
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Amgen Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. GlaxoSmithKline plc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Merck & Co., Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Novartis AG
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Multiple Myeloma Market by Drug Class
    • 4.1.1. Immunomodulators
    • 4.1.2. Proteasome Inhibitor
    • 4.1.3. Anit-CD38 Monoclonal Antibody
    • 4.1.4. Alktlating Agents
    • 4.1.5. Others
  • 4.2. Global Multiple Myeloma Market by Type
    • 4.2.1. Hyperdiploid (HMM)
    • 4.2.2. Non-Hyperdiploid or Hypodiploid
  • 4.3. Global Multiple Myeloma Market by Distribution Channel
    • 4.3.1. Hospital Pharmacies
    • 4.3.2. Retail Pharmacies & Drug Stores
    • 4.3.3. Online Pharmacies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Aurobindo Pharma
  • 6.2. Aurobindo Pharma Ltd.
  • 6.3. Bristol-Myers Squibb Co.
  • 6.4. Cipla Inc.
  • 6.5. Eli Lilly and Co.
  • 6.6. F. Hoffmann-La Roche Ltd.
  • 6.7. Fresenius Kabi AG
  • 6.8. Genentech, Inc.
  • 6.9. Hikma Pharmaceuticals PLC
  • 6.10. Karyopharm Therapeutics Inc.
  • 6.11. Oncopeptides AB
  • 6.12. Ono Pharmaceutical Co., Ltd.
  • 6.13. Sanofi S.A.
  • 6.14. Sun Pharmaceutical Industries Ltd.
  • 6.15. Takeda Pharmaceuticals U.S.A., Inc.
  • 6.16. Teva Pharmaceutical Industries Ltd.